Form 4: United Therapeutics CEO Sells Shares Under 10b5-1 Plan

United Therapeutics CEO Martine A. Rothblatt exercised stock options and sold common stock on November 20 and 21, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), reported transactions involving the exercise of stock options and subsequent sale of common stock.
• On November 20, 2025, Rothblatt acquired 4,000 shares of common stock by exercising stock options at a price of $120.26 per share.
• Also on November 20, 2025, Rothblatt sold a total of 4,000 shares of common stock in multiple trades at weighted average prices ranging from $476.8032 to $480.4422 per share.
• On November 21, 2025, Rothblatt acquired another 4,000 shares of common stock by exercising stock options at a price of $120.26 per share.
• Also on November 21, 2025, Rothblatt sold a total of 4,000 shares of common stock in multiple trades at weighted average prices ranging from $473.3145 to $476.07 per share.
• All reported transactions were executed pursuant to a pre-arranged 10b5-1 trading plan established on May 2, 2025.
• The 10b5-1 plan is set to continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025.
• Following these transactions, Rothblatt directly holds 130 shares of common stock and indirectly holds 594,353 shares through a spouse and various trusts.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions executed under a pre-arranged 10b5-1 plan, which is generally considered neutral as it's not indicative of new company-specific news or a change in management's outlook on the company's future performance.

Positives

• The transactions were conducted under a pre-arranged 10b5-1 trading plan, which enhances transparency and suggests a systematic approach to managing personal holdings rather than opportunistic selling.
• The significant difference between the option exercise price of $120.26 and the sale prices (ranging from $473.3145 to $480.4422) indicates substantial profitability for the reporting person from these option exercises.

Negatives

• The sale of common stock by a high-ranking insider, even if pre-planned, reduces their direct equity stake and could be perceived as a slight negative signal by some investors.

Future Outlook

The pre-arranged 10b5-1 trading plan, under which these transactions occurred, is scheduled to continue until the earlier of the exhaustion of a tranche of 294,000 stock options that expire on March 15, 2026, or December 31, 2025.

Management Comments

• The exercise and sale of stock options were pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025.

Industry Context

This Form 4 filing reports routine insider transactions and does not provide specific insights into broader industry trends or competitive landscape for United Therapeutics Corp.

Related Party Transactions

• Shares are held indirectly by a spouse and various family trusts, as to which the Reporting Person shares investment power and/or is a beneficiary or trustee.

Stakeholder Impact

• Shareholders: The direct equity stake of the Chairperson & CEO has slightly decreased due to these sales, though the transactions were pre-planned.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Continuation of the 10b5-1 trading plan until the earlier of the exhaustion of 294,000 stock options or December 31, 2025.

Key Dates

Recommendation

This Form 4 filing details pre-planned insider transactions (option exercises and stock sales) by the CEO under a 10b5-1 plan. Such transactions are typically for personal financial planning, diversification, or liquidity, rather than a signal about the company's immediate future performance. As these are routine and pre-scheduled, they do not provide new fundamental information that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals and market conditions.

Keywords

UTHR, United Therapeutics, Form 4, insider trading, stock options, 10b5-1 plan, executive compensation, share sale, beneficial ownership